A corporate presentation will focus on solving challenges from discovery to commercial manufacturing
Patheon, the pharmaceutical services business owned by DPx Holdings, and Banner Life Sciences will present more than 20 scientific posters at the AAPS Annual Meeting and Exposition from Sunday 2 November to Thursday 6 November in San Diego, California, US.
The AAPS Annual Meeting and Exposition hosts top scientists from CROs and CMOs in the world each year to update industry leaders on advances in the field of pharmaceutical science.
While at the conference, Patheon will feature OneSource, the end-to-end early development offering which provides a single, seamless solution to customers for Phase I through Phase II projects, delivering a simplified process for both drug substance to drug products, focusing on simplicity, speed and uncompromised quality.
In addition, Anil Kane, Executive Director, Global Formulation Sciences, PDS at Patheon, and Bill Weiser, Global Head, PDS Analytical Sciences at Patheon, will give a corporate presentation focusing on 'Solving Challenges from Discovery to Commercial Manufacturing of Drug Substance and Drug Products' on Tuesday 4 November 4, 1pm to 1.15pm in the Corporate Presentation Theatre.
'I am excited to attend AAPS again this year with our team presenting an impressive number of scientific posters that showcase our capabilities, including solving developmental challenges in manufacturing of tablets, capsules and softgels of immediate, controlled release dosage forms, as well as sterile formulations,' said Kane.
'AAPS is a leading conference in the industry, and in addition to the capabilities we will be presenting through our posters, we look forward to highlighting and introducing customers to our new OneSource offering.'
Executives, technical and scientific experts from Patheon and Banner Life Sciences will be attending AAPS and will be available to discuss the company’s full services and capabilities. Representatives can be found at booth #1014 for the duration of the conference.